Collectively, our data illustrates that inhibition of AKT-signaling pathway STS and GIST might be considered as a potent tool to enhance their sensitivity to doxorubicin, a topoisomerase II inhibitor. Here, AKT1 is linked to gastrointestinal stromal tumor.